Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: antarespharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2021 | $5.50 → $5.00 | Buy | HC Wainwright & Co. |
| 7/16/2021 | $7.00 | Buy | Truist Securities |
Submission status for ANTARES PHARMA INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares' corporate Human Resources ("HR") strategy and development. Claude E. Richardson has more than 25 years of Human Resources leadership experience across multiple industries including pharmaceutical, industrials, financial services and consumer products. His broad-based background in Human Resources includes talent management and acquisition, compensation and benefits, development and training, performance manage
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies. Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Prior to that, she was the Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she also served as the Chief Financial Officer of Tornier, NV, Spine Wave, Inc. and American Medical Systems, I
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institut
EWING, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Peter Richardson, MRCP, as Executive Vice President, Research and Development and Chief Medical Officer. In this role, Dr. Richardson will oversee the Company's proprietary research and development programs, including ideation, formulation, clinical operations, pharmacovigilance and medical affairs. Dr. Richardson has over 25 years of research and development experience in the pharmaceutical and medical device industry. He has created centers of excellence that have enabled and supported product development pipelines enc
15-12B - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
SC 13G - ANTARES PHARMA, INC. (0001016169) (Subject)
SC 13G - ANTARES PHARMA, INC. (0001016169) (Subject)
CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023. He brings an expert perspective on platform growth opportunities as a leader of multiple global biotechnology and pharmaceutical companies. Dr. Wotton is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational busines
SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") has expired. On April 26, 2022, Halozyme commenced a tender offer (the "Offer") to purchase all outstanding shares of common stock of Antares (the "Shares") for $5.60 per share in cash, without interest thereon and net of any applicable withholding taxes. As a result of the expiration of the waiting period under the HSR Act, the condition to the Offer relating to the expirat
SAN DIEGO, April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement"). The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy ("TRT") indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "The FDA approval of TLANDO brings to market an oral formulation of testosterone that we believe will prove beneficial to physicians and their patients. We have recen
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which exclu
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022. Details of the presentation are as follows: Event: Cowen 42nd Annual Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsPresentation Date: Tuesday, March 8, 2022Time: 9:50am ET A webcast of the fireside chat will be available under the "For Investors" section of the Antares Pharma website at www.antarespharma.com. A
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 9589807. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antares
EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has accepted its New Drug Application ("NDA") resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy ("TRT"). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act (PDUFA). TLANDO® was granted tentative approval from the FDA as a twice-daily oral formulation of testosterone for testosterone replacement therapy indica
EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The FDA's Fast Track designation process is designed to accelerate the development and review of treatments for serious and life-threa
HC Wainwright & Co. reiterated coverage of Antares Pharma with a rating of Buy and set a new price target of $5.00 from $5.50 previously
Truist Securities initiated coverage of Antares Pharma with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of Antares Pharma with a rating of Buy and set a new price target of $5.00 from $4.50 previously
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which exclu
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 9589807. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antares
Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "Our third quarter financial and operating results are illustrative of the strong execution that we continue to deliv
EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens. Antares will host a conference call on Thursday, November 4, 2021 at 8:30am ET to discuss the results. The dial-in numbers are (800) 353-6461 for domestic callers and (334) 323-0501 for international callers. The conference ID number is 2794616. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.co
Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today reported financial and operating results for the second quarter ended June 30, 2021 with record revenue of $45.0 million and net income of $4.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "We believe our strong second quarter performance highlights the growth opportunities that prevail across our diversified bu
EWING, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced it will release its second quarter 2021 financial and operating results on Thursday, August 5, 2021, before the market opens. Antares will host a conference call on Thursday, August 5, 2021 at 8:30am ET to discuss the results. The dial-in numbers are (800) 367-2403 for domestic callers and (334) 777-6978 for international callers. The conference ID number is 3020992. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antarespharma.com.
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter. Antares Pharma earned $32.68 million, and sales totaled $48.73 million in Q4. Why Is ROIC Significant? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Antares Pharma posted an ROIC of -1.44%. Keep in mind, w
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement"). The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of the Merger Agreement. The closing of the
Upgrades For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago quarter EPS of $2.66. The stock has a 52-week-high of $233.72 and a 52-week-low of $174.70. At the end of the last trading period, United Parcel Service closed at $188.87. According to WestPark Capital, the prior rating for Paysafe Ltd (NYSE:PSFE) was changed from Hold to Buy. The stock has a 52-week-high of $14.30 and a 52-week-low of $2.58. At the end of the last trading period, Paysafe closed at $3.25. Baird upgraded the previous rating for H.B. Fuller Co (NYSE:FUL) from Neutral to Outperf
Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is 2.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inte
Truist Securities analyst Gregory Fraser downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Hold and lowers the price target from $7 to $5.6.
Ladenburg Thalmann analyst Matthew Kaplan downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral.
Raymond James analyst Elliot Wilbur downgrades Antares Pharma (NASDAQ:ATRS) from Strong Buy to Market Perform.
HC Wainwright & Co. analyst Oren Livnat downgrades Antares Pharma (NASDAQ:ATRS) from Buy to Neutral and announces $5.6 price target.
Piper Sandler analyst David Amsellem downgrades Antares Pharma (NASDAQ:ATRS) from Overweight to Neutral and lowers the price target from $6 to $5.6.
Gainers Kaleido Biosciences (NASDAQ:KLDO) shares moved upwards by 105.3% to $0.35 during Wednesday's regular session. Kaleido Biosciences's stock is trading at a volume of 170.1 million shares as of 13:30 EST. This is 20116.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.0 million. Antares Pharma (NASDAQ:ATRS) shares increased by 49.19% to $5.58. As of 13:30 EST, this security is trading at a volume of 105.0 million shares, making up 13080.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $949.1 million. Sierra Oncology (NASDAQ:SRRA) stock rose 38.62% to $54.78. Trad